HLA-DRB1*1501 intensifies the impact of IL-6 promoter polymorphism on the susceptibility to multiple sclerosis in an Iranian population

Abstract

Background: The multifunctional cytokine interleukin-6 (IL-6) is involved in inflammatory processes in the central nervous system. It is well documented that amount of IL-6 is increased in serum, cerebrospinal fluid and central nervous system lesions of patients with multiple sclerosis. A single nucleotide polymorphism at position -174 in the IL-6 gene promotor appears to influence IL-6 expression. Recently, several researchers have focused on HLA-DRB alleles, specifically HLA-DRB1*1501, as a potential risk allele in the pathogenesis of multiple sclerosis.

Objective: To investigate the possible influence of IL-6/-174 polymorphisms on susceptibility to multiple sclerosis and its integration with HLA-DRB1*1501. Genomic DNA was extracted from whole blood of 345 patients with multiple sclerosis and 426 control subjects.

Method: The SSP-PCR method was used to determine genotypes and Fisher’s exact test was applied to determine differences between groups. HLA-DRB1*1501 was observed more frequently among multiple sclerosis patients compared with healthy subjects (45% and 34%, respectively; OR = 1.6, 95% CI = 1.2—2.2, p = 0.0018). At the IL-6/-174 position, the G allele had higher frequency among multiple sclerosis patients compared with controls (77% and 70%, respectively; OR = 1.4, 95% CI = 1.1—1.8, p = 0.0038). This difference was more significant among HLA-DRB1*1501-positive patients and controls (81% and 67%, respectively; OR = 1.9, 95% CI = 1.5—2.5, p < 0.0001).

Results: Our results have shown that the G allele at the IL-6/-174 promoter polymorphism may be associated with development of multiple sclerosis in this population, and may be strengthened by HLA-DRB1*1501.

Conclusions: We suggest more studies to confirm these results in other populations.

Keywords

genetic susceptibility HLA-DRB1*1501 interleukin 6 Iranian population multiple sclerosis

Get full access to this article

View all access options for this article.

References

Hansen T. , Skytthe A. , Stenager E. , Petersen HC , Brønnum-Hansen H. and Kyvik KO Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult Scler 2005; 11: 504-510.

Coraddu F. , Reyes-Yanez MP , Parra A. , Gray J. , Smith SI , Taylor CJ , et al. HLA associations with multiple sclerosis in the Canary Islands . J Neuroimmunol 1998; 87: 130-135.

Dyment DA , Herrera BM , Cader MZ , Willer CJ , Lincoln MR , Sadovnick AD , et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 2005; 14: 2019-2026.

International Multiple Sclerosis Genetics Consortium , Hafler DA , Compston A. , Sawcer S. , Lander ES , Daly MJ , et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.

Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC) , Burton PR , Clayton DG , Cardon LR , Craddock N. , et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39: 1329-1337.

Fernández O. , R-Antigüedad A. , Pinto-Medel MJ , Mendibe MM , Acosta N. , Oliver B. , et al. HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain). J Neurol 2009; Jul 8. [Epub ahead of print].

Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) , Bahlo M. , Booth DR , Broadley SA , Brown MA , Foote SJ , et al. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009; 41: 824-828.

Patrucco L. , Larriba J. , Redal MA , Rojas JI , Argibay PF and Cristiano E. HLA-DRB1 and multiple sclerosis in Argentina. Eur J Neurol 2009; 16: 427-429.

Stankovich J. , Butzkueven H. , Marriott M. , Chapman C. , Tubridy N. , Tait BD , et al. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis . Tissue Antigens 2009; 74: 17-21.

10.

Chao MJ , Barnardo MC , Lincoln MR , Ramagopalan SV , Herrera BM , Dyment DA , et al. HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci U S A 2008; 105: 13069-13074.

11.

Eugster HP , Frei K. , Kopf M. , Lassmann H. and Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998; 28: 2178-2187.

12.

Coraddu F. , Lai M. , Mancosu C. , Cocco E. , Sawcer S. , Setakis E. , et al. A genome-wide screen for linkage disequilibrium in Sardinian multiple sclerosis. J Neuroimmunol 2003; 143: 120-123.

13.

Harbo HF , Datta P. , Oturai A. , Ryder LP , Sawcer S. , Setakis E. , et al. Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients. J Neuroimmunol 2003; 143: 101-106.

14.

Schönrock LM , Gawlowski G. and Brück W. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci Lett 2000; 294: 45-48.

15.

Stelmasiak Z. , Kozioł-Montewka M. , Dobosz B. , Rejdak K. , Bartosik-Psujek H. , Mitosek-Szewczyk K. , et al. Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients. Med Sci Monit 2000; 6: 1104-1108.

16.

Gijbels K. , Van Damme J. , Proost P. , Put W. , Carton H. and Billiau A. Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 1990; 20: 233-235.

17.

Lock C. , Hermans G. , Pedotti R. , Brendolan A. , Schadt E. , Garren H. , et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500-508.

18.

Chung IY , Norris JG and Benveniste EN Differential tumor necrosis factor alpha expression by astrocytes from experimental allergic encephalomyelitis-susceptible and -resistant rat strains. J Exp Med 1991; 173: 801-811.

19.

Okuda Y. , Sakoda S. , Bernard CC , Fujimura H. , Saeki Y. , Kishimoto T. , et al. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein . Int Immunol 1998; 10: 703-708.

20.

Fishman D. , Faulds G. , Jeffery R. , Mohamed-Ali V. , Yudkin JS , Humphries S. , et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.

21.

Amirzargar A. , Khosravi F. , Dianat S. , Hushmand F. , Maryousef P. , Foroushani AR , et al. Profile of cytokine gene polymorphisms in Iranian multiple sclerosis patients. Mult Scler 2007; 13: 253-255.

22.

Fedetz M. , Matesanz F. , Pascual M. , Martín J. , Fernández O. , Guerrero M. , et al. The -174/-597 promoter polymorphisms in the interleukin-6 gene are not associated with susceptibility to multiple sclerosis. J Neurol Sci 2001; 190: 69-72.

23.

Mihailova S. , Ivanova M. , Mihaylova A. , Quin L. , Mikova O. and Naumova E. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J Neuroimmunol 2005; 168: 138-143.

24.

Shahbazi M. , Ebadi H. , Fathi D. , Roshandel D. , Mahamadhoseeni M. , Rashidbaghan A. , et al. CCR5-Delta32 allele is associated with the risk of developing multiple sclerosis in the Iranian population. Cell Mol Neurobiol 2009; 29: 1205-1209.

25.

McDonald WI , Compston A. , Edan G. , Goodkin D. , Hartung HP , Lublin FD , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.

26.

Shahbazi M. , Pravica V. , Nasreen N. , Fakhoury H. , Fryer AA , Strange RC , et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002; 359: 397-401.

27.

Ghabaee M. , Bayati A. , Amri Saroukolaei S. , Sahraian MA , Sanaati MH , Karimi P. , et al. Analysis of HLA DR2&DQ6 (DRB1*1501, DQA1*0102, DQB1*0602) haplotypes in Iranian patients with multiple sclerosis. Cell Mol Neurobiol 2009; 29: 109-114.

28.

Serada S. , Fujimoto M. , Mihara M. , Koike N. , Ohsugi Y. , Nomura S. , et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2008; 105: 9041-9046.

29.

Langrish CL , Chen Y. , Blumenschein WM , Mattson J. , Basham B. , Sedgwick JD , et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.

30.

Duvefelt K. , Anderson M. , Fogdell-Hahn A. and Hillert J. A NOTCH4 association with multiple sclerosis is secondary to HLA-DR*1501. Tissue Antigens 2004; 63: 13-20.